TH1940 / Tharimmune - LARVOL DELTA

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology (Streetinsider.com) - "Tharimmune, Inc...announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF), and HS3215, a dual-target biologic binding to Human Epidermal Growth Factors 2 (HER2) and 3 (HER3) receptors....Tharimmune plans to further optimize and improve binding characteristics of HS1940 and present more data at future scientific conferences. The Company expects to initiate IND-enabling studies for HS1940 in 2025."

Preclinical • Oncology • Solid Tumor

Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers (GlobeNewswire) - "Hillstream BioPharma, Inc....a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics, will be hosting a virtual R&D Day on Tuesday, February 14, 2023....HSB-1940 combines a novel anti-PD-1 Picobody with long half-life-Quatramers. Hillstream believes it could more efficiently target undruggable epitopes with greater binding affinity than approved biologics....Dana-Farber Cancer Institute (DFCI) has entered into an exclusive option agreement with Hillstream Biopharma Inc., for certain of its proprietary technology, which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis."

Licensing / partnership • Preclinical • Oncology